Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

373 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Combining a CAR and a chimeric costimulatory receptor enhances T cell sensitivity to low antigen density and promotes persistence.
Katsarou A, Sjöstrand M, Naik J, Mansilla-Soto J, Kefala D, Kladis G, Nianias A, Ruiter R, Poels R, Sarkar I, Patankar YR, Merino E, Reijmers RM, Frerichs KA, Yuan H, de Bruijn J, Stroopinsky D, Avigan D, van de Donk NWCJ, Zweegman S, Mutis T, Sadelain M, Groen RWJ, Themeli M. Katsarou A, et al. Among authors: ruiter r. Sci Transl Med. 2021 Dec 8;13(623):eabh1962. doi: 10.1126/scitranslmed.abh1962. Epub 2021 Dec 8. Sci Transl Med. 2021. PMID: 34878825 Free PMC article.
CD38 as a therapeutic target for adult acute myeloid leukemia and T-cell acute lymphoblastic leukemia.
Naik J, Themeli M, de Jong-Korlaar R, Ruiter RWJ, Poddighe PJ, Yuan H, de Bruijn JD, Ossenkoppele GJ, Zweegman S, Smit L, Mutis T, Martens ACM, van de Donk NWCJ, Groen RWJ. Naik J, et al. Among authors: ruiter rwj. Haematologica. 2019 Mar;104(3):e100-e103. doi: 10.3324/haematol.2018.192757. Epub 2018 Sep 6. Haematologica. 2019. PMID: 30190344 Free PMC article. No abstract available.
Preclinical evidence for an effective therapeutic activity of FL118, a novel survivin inhibitor, in patients with relapsed/refractory multiple myeloma.
Holthof LC, van der Horst HJ, van Hal-van Veen SE, Ruiter RWJ, Li F, Buijze M, Andersen MN, Yuan H, de Bruijn J, van de Donk NWCJ, Lokhorst HM, Zweegman S, Groen RWJ, Mutis T. Holthof LC, et al. Haematologica. 2020 Jan 31;105(2):e80-e83. doi: 10.3324/haematol.2018.213314. Print 2020. Haematologica. 2020. PMID: 31123033 Free PMC article. No abstract available.
CD38-specific Chimeric Antigen Receptor Expressing Natural Killer KHYG-1 Cells: A Proof of Concept for an "Off the Shelf" Therapy for Multiple Myeloma.
Stikvoort A, van der Schans J, Sarkar S, Poels R, Ruiter R, Naik J, Yuan H, de Bruijn JD, van de Donk NWCJ, Zweegman S, Themeli M, Groen R, O'Dwyer M, Mutis T. Stikvoort A, et al. Among authors: ruiter r. Hemasphere. 2021 Jun 12;5(7):e596. doi: 10.1097/HS9.0000000000000596. eCollection 2021 Jul. Hemasphere. 2021. PMID: 34131635 Free PMC article.
Specific Targeting of Multiple Myeloma by Dual Split-signaling Chimeric Antigen Receptor T cells Directed against CD38 and CD138.
van der Schans JJ, Wang Z, van Arkel J, van Schaik T, Katsarou A, Ruiter R, Baardemans T, Yuan H, de Bruijn J, Zweegman S, van de Donk NWCJ, Groen RWJ, Themeli M, Mutis T. van der Schans JJ, et al. Among authors: ruiter r. Clin Cancer Res. 2023 Oct 13;29(20):4219-4229. doi: 10.1158/1078-0432.CCR-23-0132. Clin Cancer Res. 2023. PMID: 37527004
Preclinical evaluation of the CD38-targeting engineered toxin body MT-0169 against multiple myeloma.
Bruins WSC, Rentenaar R, Newcomb J, Zheng W, Ruiter RWJ, Baardemans T, Poma E, Moore C, Robinson GL, Lublinsky A, Zhang Y, Syed S, Milhollen M, Dash AB, van de Donk NWCJ, Groen RWJ, Zweegman S, Mutis T. Bruins WSC, et al. Among authors: ruiter rwj. Hemasphere. 2024 Nov 14;8(11):e70039. doi: 10.1002/hem3.70039. eCollection 2024 Nov. Hemasphere. 2024. PMID: 39544624 Free PMC article.
373 results